ِAbout Us
STIO is an Egyptian family-owned Private Joint Stock company established in 2016 with an authorized capital of EGP 500 million and a paid-in capital of EGP 100 million.
Since our founding, we have specialized in advanced therapies for cardiovascular health, respiratory care, sedation, and pain management. Our mission is to localize the production of high-quality pharmaceuticals while addressing the specific needs of Egypt, Africa, and the Middle East.
DR Mohamed Amr Abdelrazik
Message from the Chairman
At STIO, we believe that healthcare is not just about medicine—it’s about making a difference in people’s lives. Since our establishment, we have been committed to providing high-quality, accessible, and innovative pharmaceutical solutions that address critical healthcare needs.
Join us and make an impact!
Your journey to success starts here
Why STIO ?
Quality
Commitment to providing safe and effective products that meet global standards.
Innovation
Leveraging research and advanced technology to develop cutting-edge medical solutions.
Transparency
Upholding integrity and honesty in all our operations.
Impact
Striving to improve lives by making effective treatments accessible.
our Products
Our ability to deliver outstanding results for our clients
starts with our team of experts.
Meet our Board
Our ability to deliver outstanding results for our clients
starts with our team of experts.
DR Mohamed Amr Abdelrazik
Chairman of Stio Life Science.
Ms Omima Ramadan
Vice Chairman of Stio Life Science.
DR Ashraf Sadek
Chief Executive Officer
Dr Gamal Awad
Chief Financial Officer
Board Member of Stio Life Science.
Dr Mahmoud Amr
General Manager
Board Member of Stio Life Science.
Ms Hadeer Amr
Vice Chief Financial Officer
Board Member of Stio Life Science.
Partners
Our Partners
At STIO, we believe that strong partnerships are the foundation of innovation and progress in healthcare.
